SEC 13F Intelligence

Orbimed Advisors LLC / ELVN

Orbimed Advisors LLC’s Enliven Therapeutics Inc Position

Does Orbimed Advisors LLC own Enliven Therapeutics Inc (ELVN)? Yes7.96M shares worth $312M (+6.18% of its 13F portfolio) as of Q1 2026.

Position Value
$312M
Q1 2026
Shares
7.96M
% of Portfolio
+6.18%
Quarters Held
13
currently held

Position History ELVN

Reported value by quarter
Q1 ’23: $197MQ1 ’23Q2 ’23: $184MQ3 ’23: $123MQ3 ’23Q4 ’23: $125MQ1 ’24: $158MQ1 ’24Q2 ’24: $186MQ3 ’24: $203MQ3 ’24Q4 ’24: $179MQ1 ’25: $157MQ1 ’25Q2 ’25: $160MQ3 ’25: $163MQ3 ’25Q4 ’25: $123MQ1 ’26: $312MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20267.96M$312M+6.18%
Q4 20257.96M$123M+2.50%
Q3 20257.96M$163M+3.83%
Q2 20257.96M$160M+3.99%
Q1 20257.96M$157M+3.73%
Q4 20247.96M$179M+3.68%
Q3 20247.96M$203M+3.69%
Q2 20247.96M$186M+3.67%
Q1 20249.00M$158M+2.90%
Q4 20239.00M$125M+2.49%
Q3 20239.00M$123M+2.61%
Q2 20239.00M$184M+3.33%
Q1 20239.00M$197M+3.87%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Orbimed Advisors LLC’s full portfolio or all institutional holders of ELVN.